Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2019
Subject: Pre-announcement of unaudited fourth quarter 2018 global net product revenues for ONPATTRO (patisiran) and updates on commercial launch and cash guidance.
Key Financial Metrics
- Q4 2018 Revenue (ONPATTRO): $11 million to $12 million (unaudited).
- Cash Position (Year-End 2018 Guidance): Expected to end 2018 with $1.1 billion (unaudited) in cash, cash equivalents, marketable securities, and restricted investments, excluding securities.
- Profit, Margins, and Debt: The filing text does not provide clear values for net income, operating margins, or specific debt figures.
Material Changes
This filing represents a pre-announcement of financial results prior to the formal release of the full quarterly report. The primary material update is the specific revenue range for the newly launched product ONPATTRO and the revised cash guidance for the fiscal year ending December 31, 2018.
Guidance, Outlook, and Risks
- Guidance Update: Management updated its cash guidance, projecting $1.1 billion in total liquid assets at year-end 2018.
- Commercial Update: The company provided additional updates on the commercial launch of ONPATTRO.
- Legal Disclaimer: The information in Item 2.02 and the attached press release is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the final audited Q4 2018 revenue figures in the subsequent 10-Q or 10-K filing.
- Confirm the actual year-end 2018 cash balance against the $1.1 billion guidance.
- Review the full press release (Exhibit 99.1) for detailed commercial launch metrics not included in this summary.
- Monitor future filings for updates on the profitability timeline for ONPATTRO.